Story perspectives

FDA Delays Bitopertin Approval Amid Efficacy Concerns

2/17/2026

Summary

Story summary

U.S. Food and Drug Administration (FDA) has requested data from Disc Medicine for bitopertin, delaying approval to treat erythropoietic protoporphyria.
The FDA's response cited concerns about efficacy, noting a 40% reduction in protoporphyrin IX that may not translate to clinical benefit.
The decision followed Moderna's mRNA flu vaccine rejection, raising questions about FDA review consistency.
Disc plans to complete its Phase 3 study by March 2027, supporting a future resubmission.

1 of 1

Story summary

U.S. Food and Drug Administration (FDA) has requested data from Disc Medicine for bitopertin, delaying approval to treat erythropoietic protoporphyria.
The FDA's response cited concerns about efficacy, noting a 40% reduction in protoporphyrin IX that may not translate to clinical benefit.
The decision followed Moderna's mRNA flu vaccine rejection, raising questions about FDA review consistency.
Disc plans to complete its Phase 3 study by March 2027, supporting a future resubmission.